The pharmacokinetics and pharmacodynamics of zoledronic acid in cancer patients with varying degrees of renal function. - Wikidata - awgldk - TriplyDB

The pharmacokinetics and pharmacodynamics of zoledronic acid in cancer patients with varying degrees of renal function.

The pharmacokinetics and pharmacodynamics of zoledronic acid in cancer patients with varying degrees of renal function.

http://www.wikidata.org/entity/Q44343595

about

Human isoprenoid synthase enzymes as therapeutic targets γδ T cells for cancer immunotherapy: A systematic review of clinical trials Nanoparticles for the delivery of zoledronic acid to prostate cancer cells: a comparative analysis through time lapse video-microscopy technique.Endocytotic uptake of zoledronic acid by tubular cells may explain its renal effects in cancer patients receiving high doses of the compound Zoledronic Acid and renal toxicity: data from French adverse effect reporting database.Activity of mevalonate pathway inhibitors against breast and ovarian cancers in the ATP-based tumour chemosensitivity assay.A novel soft-tissue in vitro model for bisphosphonate-associated osteonecrosis Zoledronic acid directly suppresses cell proliferation and induces apoptosis in highly tumorigenic prostate and breast cancers.A Novel Prothrombotic Pathway in Systemic Sclerosis Patients: Possible Role of Bisphosphonate-Activated γδ T Cells.Zoledronic acid produces combinatory anti-tumor effects with cisplatin on mesothelioma by increasing p53 expression levels.Role of zoledronic acid in the prevention and treatment of osteoporosis.Safety and tolerability of zoledronic acid and other bisphosphonates in osteoporosis management.A phase I study of zoledronic acid and low-dose cyclophosphamide in recurrent/refractory neuroblastoma: a new approaches to neuroblastoma therapy (NANT) study.Unbiased analysis of pancreatic cancer radiation resistance reveals cholesterol biosynthesis as a novel target for radiosensitisation The impact of menopause on bone, zoledronic acid, and implications for breast cancer growth and metastasis.Effective combination treatment of GD2-expressing neuroblastoma and Ewing's sarcoma using anti-GD2 ch14.18/CHO antibody with Vγ9Vδ2+ γδT cells.Effect of zoledronic acid on oral fibroblasts and epithelial cells: a potential mechanism of bisphosphonate-associated osteonecrosis Bisphosphonates induce the osteogenic gene expression in co-cultured human endothelial and mesenchymal stem cells.Panobinostat synergizes with zoledronic acid in prostate cancer and multiple myeloma models by increasing ROS and modulating mevalonate and p38-MAPK pathways.Zoledronic acid: an unending tale for an antiresorptive agent.Pharmacokinetic evaluation of zoledronic acid.Zoledronic acid: multiplicity of use across the cancer continuum.Hypercalcemia in the Intensive Care Unit: A Review of Pathophysiology, Diagnosis, and Modern Therapy.γδ T Lymphocytes as a First Line of Immune Defense: Old and New Ways of Antigen Recognition and Implications for Cancer Immunotherapy.Comparison of the anti-tumor effects of denosumab and zoledronic acid on the neoplastic stromal cells of giant cell tumor of bone.Self-assembling nanoparticles for the release of bisphosphonates in the treatment of human cancers [WO2012042024].Anti-tumour and anti-angiogenetic effects of zoledronic acid on human non-small-cell lung cancer cell line.Issues in the safety testing of metabolites.Zoledronic acid augments the radiosensitivity of cancer cells through perturbing S- and M-phase cyclins and p21CIP1 expression.Bisphosphonates and cancer: what opportunities from nanotechnology?Zoledronate inhibits proliferation and induces apoptosis of imatinib-resistant chronic myeloid leukaemia cells.Safety, pharmacokinetics, and changes in bone metabolism associated with zoledronic acid treatment in Japanese patients with primary osteoporosis.Effect of zoledronate, a third-generation bisphosphonate, on proliferation and apoptosis of human dental pulp stem cells.p53-independent anti-tumor effects of the nitrogen-containing bisphosphonate zoledronic acid.Valproic Acid Combined with Zoledronate Enhance γδ T Cell-Mediated Cytotoxicity against Osteosarcoma Cells via the Accumulation of Mevalonate Pathway Intermediates.Renal Safety and Pharmacokinetics of Ibandronate in Multiple Myeloma Patients With or Without Impaired Renal Function Zoledronate inhibits fibroblasts' proliferation and activation via targeting TGF-β signaling pathway Is retention of zoledronic acid onto bone different in multiple myeloma and breast cancer patients with bone metastasis?

P2860

Q26822639-ADF01130-F5AD-4AB3-9B59-68B26EB54319 Q27021705-A6C9F37E-3899-4210-BD92-D166F3EA25EA Q27302083-94FDE34D-750F-45DC-BEC3-83ADF7C75080 Q28543939-C233FF6B-22AB-4D0A-A180-9024B01C3EDB Q30992052-615FEB3B-BFF1-4C2A-8807-BAD1B626D1BC Q33403655-FBE09F4C-EB8E-42ED-A648-C77544E855D9 Q33810748-841A2E45-D4E5-45C2-8920-7F0913778C58 Q34025648-6DCB0F6F-F67A-4287-89C9-C1CA5B5ADDF9 Q34148693-082F97C7-5283-4ECB-9BC0-FF740CC48D6A Q34653709-40883719-E144-4D93-AB72-E115D40F8D2B Q34984177-3865FD03-7713-4971-9FBE-BAC6C5313B88 Q35026446-99B737E8-ADE2-4E1C-AB91-D3486CFE3AB9 Q35050731-151E1128-D249-4F2E-929B-BE488E0EEEA9 Q35678372-D9B8BD1F-5741-4D51-AB52-06F1199B786D Q36337775-BBFC39B3-C9FC-4D52-96CE-ED71C43117B1 Q36597374-7EF507AD-61EB-4978-BB07-9F7BAFE4A9E6 Q37336300-FCF6B093-275E-4597-8178-6A46F0A4BC02 Q37562322-AECDA736-DE22-496E-B6F6-8C6E4FCCCB86 Q37577433-A7EA5E7C-7373-437E-BFA9-00510CAEF5F8 Q37650334-3ED229F6-1ACF-45B3-8E12-A4464B91F1DD Q37874629-21F94538-9642-495A-818A-E228ED873AFD Q37909355-2FC0B8B2-8F40-468D-AEBA-96F53F84F7B5 Q38153026-27DEE230-C069-4797-85F5-2E9CBDBC0B5E Q38271585-DDC9F5BA-7BC5-4E3F-9299-66ED180E24D3 Q39092826-4A1F4227-3F5E-4D19-AA4E-6381583A2040 Q39290416-C961AA76-F161-43CB-9212-E941FADB50B9 Q39576482-7565DBAA-0375-460A-889E-A9BC51685650 Q39934028-3411533C-478C-41F5-B70B-2D74A0C0D2A3 Q41701781-D96E16C7-72D3-49B2-91B6-912CC34E01AE Q41829362-B143B411-A80E-4D97-8230-D78DC8EA8DC9 Q46706721-78FF7611-9383-492C-9335-E934D56977A9 Q47912290-4FF79749-FF9A-45D6-B664-26B1D45CC1EE Q47994742-B8A81BDF-5774-40E1-8A97-74B032613E26 Q51035665-E58F1135-70B0-4C08-9B23-AEB93BE49B9E Q52657143-8052DAB9-8450-4488-B111-C10B448021AF Q56832283-B1AEFFAB-5BA3-45D6-9530-A6E85FBCCBE7 Q57074336-052968F8-C3E2-4680-BDC0-77163AEA81DE Q57566233-6EAB51A3-5B41-476E-BF95-EB0D154012F6

P2860

The pharmacokinetics and pharmacodynamics of zoledronic acid in cancer patients with varying degrees of renal function.

http://www.wikidata.org/entity/Q44343595

description

2003 nî lūn-bûn

@nan

2003年の論文

@ja

2003年学术文章

@wuu

2003年学术文章

@zh-cn

2003年学术文章

@zh-hans

2003年学术文章

@zh-my

2003年学术文章

@zh-sg

2003年學術文章

@yue

2003年學術文章

@zh

2003年學術文章

@zh-hant

name

The pharmacokinetics and pharm ...... ing degrees of renal function.

@en

The pharmacokinetics and pharm ...... ing degrees of renal function.

@nl

type

label

The pharmacokinetics and pharm ...... ing degrees of renal function.

@en

The pharmacokinetics and pharm ...... ing degrees of renal function.

@nl

prefLabel

The pharmacokinetics and pharm ...... ing degrees of renal function.

@en

The pharmacokinetics and pharm ...... ing degrees of renal function.

@nl

P1433

Q44343595-8C3E38AD-6E4A-468D-B29A-3769073DD420

P1476

Q44343595-C9675EDB-95E5-44D9-855F-A6F85DB5D181

P2093

Q44343595-38B004B6-E305-4145-8CE3-338E610CFD56

Q44343595-478AE985-7756-4E1D-8461-8ADBCF4D7BD3

Q44343595-4831F940-CDDF-4324-BCA9-233E2E5D6145

Q44343595-790575A7-D64D-43E6-8A6A-821B81F05A40

Q44343595-9F828CDB-656F-40AD-93F0-79F7A57BC912

Q44343595-B0991512-382E-4034-AB41-0F1850FCDBB2

Q44343595-B22B7F64-3D90-4764-AFE5-7A0403A7DEF1

Q44343595-E10472DD-350A-4C4A-814A-BE9DB6EE4EE0

Q44343595-EF2A2B9A-D5DB-4D67-9819-53EB518A6AAF

P2860

Q44343595-0AF533F8-A6A7-43B8-9780-B3FF48EE2A94

Q44343595-1D16A2B4-905D-493C-9470-3E47F4533DC3

Q44343595-1E90BA57-12A5-49A2-914D-D10E17692019

Q44343595-26BC41BA-ADE2-4A2D-88F1-C99DC7855800

Q44343595-28CA5EC4-8C46-4977-956A-D0F0867AAE55

Q44343595-315C1B03-5ACE-4178-96F0-5F929AB7EA61

Q44343595-3E572A99-910D-4AAE-82BD-20688795031E

Q44343595-45D649FE-12FD-4D54-9619-6A8AABC9FBD8

Q44343595-5E7DA412-EDC9-4704-82EC-E116CDCE67AB

Q44343595-77F50901-EA53-42F7-8CED-F651B13AA396

P304

Q44343595-6A6DCEE2-9B5D-4B51-B968-9F36C5CF492C

P31

Q44343595-39831DB7-CA4F-4089-B2F9-AF1878CB2FF9

P356

Q44343595-2236A6AC-260F-4A2A-B989-94A197BD9279

P433

Q44343595-B16F3AA8-16E0-4DFD-BC74-7E66F435CD87

P478

Q44343595-417FF171-51CD-4383-A326-D2AE7A4A091C

P577

Q44343595-60D12378-A148-4514-AC35-03CCF40E35BC

P698

Q44343595-3C25D265-744A-4F45-8F46-49235FCA328D

P356

0091270002239824

P1433

The Journal of Clinical Pharmacology

P1476

The pharmacokinetics and pharm ...... ing degrees of renal function.

@en

P2093

Andrej Skerjanec

http://www.w3.org/2001/XMLSchema#string

Christina Ravera

http://www.w3.org/2001/XMLSchema#string

ChyiHung Hsu

http://www.w3.org/2001/XMLSchema#string

Felix Waldmeier

http://www.w3.org/2001/XMLSchema#string

Horst Schran

http://www.w3.org/2001/XMLSchema#string

James Berenson

http://www.w3.org/2001/XMLSchema#string

John Seaman

http://www.w3.org/2001/XMLSchema#string

Pierre Major

http://www.w3.org/2001/XMLSchema#string

Wilson H Miller

http://www.w3.org/2001/XMLSchema#string

P2860

Prediction of creatinine clearance from serum creatinine

Bisphosphonates and the prevention of metastasis: first evidences from preclinical and clinical studies.

Chemical and biological prerequisites for novel bisphosphonate molecules: results of comparative preclinical studies.

Zoledronic acid in cancer patients with bone metastases: results of Phase I and II trials.

Bisphosphonates in the prevention of bone metastases: current evidence.

The effect of dosing regimen on the pharmacokinetics of risedronate.

Effect of renal function on risedronate pharmacokinetics after a single oral dose

Pharmacokinetics of pamidronate disodium in patients with cancer with normal or impaired renal function.

Bisphosphonates: a review of their pharmacokinetic properties.

Adverse effects of bisphosphonates. A comparative review.

P304

154-162

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1177/0091270002239824

http://www.w3.org/2001/XMLSchema#string

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

43

http://www.w3.org/2001/XMLSchema#string

P577

2003-02-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

12616668

http://www.w3.org/2001/XMLSchema#string